Find A Research Study
Study Title: Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (RTOG 0524)
Category: Cancer, General
Currently accepting participants?
Yes - please read the description below and contact the study coordinator if you are interested.
Principal Investigator: Huong Pham
Study Coordinator: Kathy Rabena
Phone: (206) 223-6892 Ext.36892
Email: hemkcr@vmmc.org
What is the Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (RTOG 0524) study?
Group 1: Patients with Her2/Neu overexpression (Radiation plus Chemotherapy with Paclitaxel and Trastuzumab)
Group 2: Patients without Her2/Neu overexpression
(Radiation plus Chemotherapy with Paclitaxel)
Who can participate?
Eligibility:
~Histologically or cytological confiramtion of Transitional Cell Carcinoma (TCC) of the bladder with mauscularis propria invasion.
~Must be registered within 12 weeks of diagnosis
~Judged to be medically inapporiate for radical cystectomy
~Must have sufficient tumore tissue available for her2/neu analysis
Ineligibility:
~Prior invasive mailignancy unless disease free for a minimum of 3 years
~Previous systemice chemotherapy of any sort for TCC
~Previous radiation therapy (includes seed implantation)
Study Summary:
"A Phase I/II Trial of Combination of Paclitaxel and Trastuxuman with Daily Irradiation or Paclitaxel Alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer"
Detailed Study Description:
(No information)
Study Design: Interventional
Phase of Study: Phase I / II
Study Type: Interventional
Condition or Study Focus: Bladder Cancer
Intervention Type: biological
Intervention Name: Trastuzumab
Gender: Male and Female
Age group: Interventional
Sponsor: Radiation Therapy Oncology Group
Other studies in this category include:
Studies currently accepting study participants:
- A Phase II Study of Neoadjuvant Therapy with Cisplatin, Docetaxel, Panitumumab Plus Radiation Therapy Followed by Surgery in Patients with Locally Advanced Adenocarcinoma of the Distal Esophagus
- A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas
- AMC045: HIV-Associated Anal Cancer
- Brain Metastases in NSCLC (RTOG 0320)
- Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy
- Investigating Proteomic Biomarkers of Radiation Therapy Outcome: A Pilot Study
- Liver Cancer (Hepatocellular Carcinoma): Sorafenib vs Placebo as Adjuvant Treatment
- Liver Cancer (Hepatocellular Carcinoma): TACE for Intermediate Stage
- Lymphoma (S0313)
- Maintenance therapy for advanced ovarian or peritoneal cancer (GOG 0212)
- Newly diagnosed, untreated ovarian or peritoneal cancer (GOG 0218)
- Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (RTOG 0524)
- Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
- Sorafenib v. Sunitinib v. Placebo for High Risk Renal Cell Carcinoma Patients
- SWOG S0016
- Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced RCC Who Failed First-Line Sunitinib
- Trial of FOLFOX with or without cetuximab for colon cancer
Studies currently not accepting study participants:
- Colorectal: A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
- Investigational drug vs. Placebo for Patients with Renal Cell Carcinoma (Kidney Cancer) at High Risk of Recurrence after Surgery
- Kidney Cancer (Renal Cell Carcinoma): Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT)
- Liver Cancer (Hepatocellular Carcinoma): Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable (Advanced or Metastatic) Liver Cancer
- Methylphenidate in Treating Patients With Fatigue Caused by Cancer
- MK0646 for Patients with Advanced Cancer
- Open Label Study of Human Corticotropin-Releasing Factor (hCRF)
- Phase I, oral agent for Advanced Cancers
- Randomized Study comparing Human Corticotropin-Releasing Factor to Placebo for Patients Requiring High-dose Dexamethasone
- Stage IV Urothelial Cancer
- Use of Human Corticotropin-Releasing Factor (hCRF) to Control Brain Swelling (edema) in Brain Tumor Patients
- Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer
- Weekly Topotecan (HyCamtin®) with Bevacizumab (Avastin®) Ovarian, Fallopian tube and/or Peritoneal Cancer